title: Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression?
abstract: The symptoms of emotional dysregulation associated with the syndrome known as pseudobulbar affect (PBA) can be effectively treated by the sigma, glutamate, and serotonergic agent dextromethorphan combined with quinidine. If the same brain circuits affected in PBA are also compromised in related disorders of emotional expression, dextromethorphan-quinidine and other novel sigma-glutamate-serotonin agents could prove to be novel psychopharmacologic treatments for these conditions as well.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Stahl
mesh_terms: D003915:Dextromethorphan / Q000627:therapeutic use*; D004338:Drug Combinations; D004644:Emotions; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008962:Models, Theoretical; D020828:Pseudobulbar Palsy / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D011600:Psychopharmacology; D011802:Quinidine / Q000627:therapeutic use*; D017470:Receptors, Glutamate / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D017480:Receptors, sigma / Q000378:metabolism
chemical_list: D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists; D017470:Receptors, Glutamate; D011985:Receptors, Serotonin; D017480:Receptors, sigma; C507057:dextromethorphan - quinidine combination; D003915:Dextromethorphan; D011802:Quinidine